Dr. Rebecca Whiting's research focuses on therapeutic interventions for retinal degenerative and neurodegenerative diseases. Dr. Whiting works closely with Dr. Martin Katz and collaborators from the College of Veterinary Medicine to develop and evaluate potential therapies in a canine model of neuronal ceroid lipofuscinosis, a rare pediatric inherited disease that results in progressive degeneration of the retina and central nervous system. Preclinical studies performed by the team were instrumental in FDA approval of Brineura enzyme replacement therapy, the first available treatment for children with this disease. The research group recently received a five year NIH award to investigate the use of genetically modified mesenchymal stem cells for sustained delivery of the deficient lysosomal enzyme to the retina and brain in order to preserve vision in the dog model.
- Therapeutic intervention for retinal degenerative and neurodegenerative disease
- Objective measures of visual function
Areas of Expertise
- Retinal degeneration
- Large animal models
- In vivo retinal imaging
Education & Training
University of Missouri, PhD in Biological Engineering
Illinois Institute of Technology, Chicago, IL, BS in Biomedical Engineering
Awards & Honors
- 2018 NCL International Conference, Best Poster Award for Translational Research
- 2016 National Eye institution Travel Grant to present at the Association for Research in Vision and Ophthalmology (ARVO) 2016 Annual Meeting
View Dr. Whiting's publications on PubMed.